Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 8/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.38 |
| ▸ | CDC42BPB | Q9Y5S2 | 7/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836492 | 1.00 | KCNH2 (0.39) | KCNH2CLK1DYRK1AROCK2ROCK1 | |
| SCHEMBL23762196 | 0.86 | CDC7 (0.38) | DYRK1AROCK2ROCK1CDC42BPBMET | |
| SCHEMBL29836411 | 0.83 | CDC7 (0.41) | ROCK2METACVR1 | |
| SCHEMBL21591772 | 0.83 | CDC7 (0.41) | ROCK2METACVR1 | |
| SCHEMBL21593089 | 0.83 | BUB1 (0.37) | ROCK2ROCK1CDC42BPBMETCDC42BPA | |
| SCHEMBL29836498 | 0.83 | BUB1 (0.37) | ROCK2ROCK1CDC42BPBMETCDC42BPA | |
| SCHEMBL21591764 | 0.83 | CYP1A2 (0.43) | DYRK1AROCK2ROCK1CDC42BPA | |
| SCHEMBL29836349 | 0.83 | CYP1A2 (0.43) | DYRK1AROCK2ROCK1CDC42BPA | |
| SCHEMBL21591763 | 0.82 | CDC7 (0.35) | DYRK1AROCK2ROCK1METCDC42BPA | |
| SCHEMBL21591781 | 0.82 | CLK4 (0.50) | ROCK2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807273-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-08-03 | — | — | EP | claimed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | claimed |
| EP-3807273-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2021-04-21 | — | — | EP | claimed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | claimed |
| EP-3807273-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-08-03 | — | — | EP | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | KCNH2 2539/4885CLK1 2786/4885DYRK1A 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.